Treats overactive bladder with symptoms of urge urinary incontinence, urgency, and…. ANDA 215761, held by Annora Pharma. Solifenacin Succinate.
As of Nov 16, 2026, ANDA 215761 (Solifenacin Succinate), held by Annora Pharma, was first approved by FDA on Jun 15, 2022, with 0 approved supplements and 0 published complete response letters.
Solifenacin succinate tablets are indicated for the treatment of adults with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 15, 2022 | Original application | Approved | None posted |
| Solifenacin Succinate5MG · tablet;oral | Solifenacin Succinate | Rx |
| Solifenacin Succinate10MG · tablet;oral | Solifenacin Succinate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters